Document is current
Any future updates will be listed below
-
Authors
Dineen, Sean https://orcid.org/0000-0002-2012-2238
Mullinax, John
- License Information
-
More Information
Article History
Received: 25 August 2025
Accepted: 25 August 2025
First Online: 9 September 2025
Disclosure
: Sean Dineen has received consulting fees from Oncoinvent for activities not related to this manuscript. John Mullinax has participated in sponsored research agreements with Iovance Biotherapeutics, Intellia Therapeutics, and SQZ Biotech; has received research support from the NIH-NCI (K08CA252642), Ocala Royal Dames, and V Foundation; and has received ad hoc consulting fees from Merit Medical, Lyell Immunopharma, and Iovance Biotherapeutics. Moffitt Cancer Center has licensed Intellectual Property (IP) related to the proliferation and expansion of tumor-infiltrating lymphocytes to Iovance Biotherapeutics. John Mullinax is an inventor on such Intellectual Property.
